NICE issues draft guidance against Aimovig® (erenumab)

In a draft guidance issued this week, NICE (London, UK) has recommended against the routine NHS use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month, and where at least three other preventive treatments haven’t worked.